Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer

Expert Review of Anticancer Therapy

Volumn 16, Issue 1, 2016, Pages 13-20

  Dang, Thu Oanh ^a   Ogunniyi, Adebayo ^a   Barbee, Meagan S ^b   Drilon, Alexander ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Barbee Oncology Consulting   (United States)

Author keywords

Anti PD 1 monoclonal antibody; lambrolizumab; MK 3475; non small cell lung cancer; PD 1 inhibitor; pembrolizumab; SCH 900,475

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; IPILIMUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ANEMIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BRAIN METASTASIS; BULLOUS PEMPHIGOID; CANCER CHEMOTHERAPY; COLITIS; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; GENE MUTATION; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOPIGMENTATION; HYPOTHYROIDISM; INFUSION RELATED REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHRITIS; NEUROMUSCULAR JUNCTION DISORDER; NON SMALL CELL LUNG CANCER; OPTIC NEURITIS; OVERALL SURVIVAL; PATIENT SELECTION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHABDOMYOLYSIS; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; LUNG NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT;

EID: 84955171240     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2016.1123626     Document Type: Article

References (33)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29.
2. Ferlay J, Soerjomataram I, Ervik M., et al. GLOBOCAN 2012, version 1.0. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon (France): International Agency for Research on Cancer; 2013.
3. Ettinger DS, Wood DE, Akerley W., et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): non-small cell lung cancer. Version 7. 2015. National Comprehensive Cancer Network. [ cited 2015 Aug[. Available from: http://.www.nccn.org/professionals/physician-gls/pdf/nscl.pdf
4. Kris MG, Johnson BE, Berry LD., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311 (19): 1998-2006.
5. Schreiber RD, Old LJ, Smyth MJ., et al. Cancer immunoediting: integrating immunitys roles in cancer suppression and promotion. Science. 2011; 331: 1565-1570.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264.
7. Lawrence MS, Stojanov P, Polak P., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499 (7457): 214-218.
8. Vogelstein B, Papadopoulos N, Velculescu VE., et al. Cancer genome landscapes. Science. 2013; 339 (6127): 1546-1558.
9. Pembrolizumab (Keytruda®). Prescribing information. Whitehouse Station (NJ): Merck Sharp & Dohme Corp.; 2014 [ cited 2015 Nov 2[. Available from: http://www.merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pdf
10. Tabrizi MA, Tseng C-ML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Disc Today. 2006; 11: 81-88.
11. Huang SM, Zhao H, Lee JI., et al. Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther. 2010; 87 (4): 497-503.
12. Patel SP, Kurzrock R. PD-L1 expression as predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015; 14 (4): 847-856.
13. Wang A, Wang HY, Liu Y., et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. 2015; 41 (4): 450-456.
14. Carbognin L, Pilotto S, Milella M., et al. Differential activity of nivolumab, pembrolizumab, and MPDL3280A according to the tumor expression of programmed death-ligand 1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015; 10 (6): e0130142.
15. Garon EB, Rizvi NA, Hui R., et al., et al. Pembrolizumab for the treatment of Non-Small cell lung Cancer. New Engl J Med. 2015; 372: 2018-2028.
16. Rizvi NA, Garon EB, Leighl N., et al. Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): updated data from KEYNOTE-001. J Clin Oncol. 2015; 33 (suppl; abstr 8026).
17. Patnaik A, Socinski MA, Matthew A., et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J Clin Oncol. 2015; 33 (suppl; abstr 8011).
18. Papadimitrakopoulou V, Patnaik A, Borghaei H., et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. J Clin Oncol. 2015; 33 (suppl; abstr 8031).
19. Goldberg SB, Gettinger SN, Mahajan A., et al. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol. 2015; 33 (suppl; abstr 8035).
20. Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol. 2015. DOI: 10.1001/jamaoncol.2015.2274. [Epub ahead of print].
21. Barbee MS, Ogunniyi A, Horvat TZ., et al. Current status and future directions of immune checkpoint inhibitors of ipilimumab, pembrolizumab and nivolumab in oncology. Ann Pharmacotherapy. 2015; 49 (8): 907-937.
22. Kris MG, Hellmann MD, Chaft JE. Chemotherapy for lung cancers: here to stay. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting; 2014. p. e375-380. Available from: http://meetinglibrary.asco.org/sites/meetinglibrary.asco.org/files/edbook-pdf/2014-EdBook.pdf
23. Sandler A, Gray R, Perry MC., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
24. Pao W, Miller V, Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101: 13306-13311.
25. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11: 473-481.
26. Wolchok JD, Hoos A, ODay S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412-7420.
27. Postow MA. Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting. Vol. 35; 2015. p. 76-83. Available from: http://meetinglibrary.asco.org/sites/meetinglibrary.asco.org/files/edbook-pdf/2015-EdBook.pdf
28. Merck Sharp & Dohme Corp. A Phase II/III randomized trial of two doses of MK-3475 (SCH900475) versus docetaxel in previously treated subjects with non-small cell lung cancer. In: ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [ cited 2015 Aug 28[. Available from: https://clinicaltrials.gov/ct2/show/NCT01905657. NLM Identifier: NCT01905657.
29. Merck Sharp & Dohme Corp. A Phase I/II study of MK-3475 (SCH900475) in combination with chemotherapy or immunotherapy in patients with locally advanced or metastatic non-small cell lung carcinoma. In: ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [ 2015 Aug 28[. Available from: https://clinicaltrials.gov/ct2/show/NCT02039674. NLM Identifier: NCT02039674.
30. Brahmer JR, Kim ES, Zhang J., et al. KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). J Clin Oncol. 2015; 33 (suppl; abstr TPS8103).
31. Mok T, Wu YL, Watson PA., et al. Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2015; 33 (suppl; abstr TPS8105).
32. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27: 450-461.
33. Rizvi NA, Hellmann MD, Snyder A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348: 124-128.